As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Jerry Hughes has selected topical, interesting papers for your perusal that also include interesting articles from the emerging economic regions and publications on COVID-19 and CML.

Read Professor Hughes' CML publications of the month: March 2021

Clinical papers

• Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy
  Cortes JE et al. Eur J Haematol, February 2021 (epub ahead of print)
• Early BCR-ABL kinetics are predictive of subsequent achievement of treatment-free-remission in CML
  Shanmunagathan N et al. Blood, March 2021
• Third-line therapy for chronic myeloid leukemia: Current status and future directions
  Cortes J and Lang F. J Hematol Oncol, March 2021 – open access publication
• Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
  Radich JP et al. Leukemia, March 2021 (epub ahead of print) – open access publication
• Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
  Schäfer V et al. J Cancer Res Clin Oncol, March 2021 (epub ahead of print)  – open access publication
• Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates
  Atallah EL et al. Leuk Lymphoma, March 2021 (epub ahead of print)
• The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study
  Martínez-López J et al. Leuk Lymphoma, March 2021 (epub ahead of print)
• Should I rock the boat? When to stop TKI’s in CML?
  Nazha A. Blood, March 2021

Scientific papers

• Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study
  Ottmann OG et al. Leuk Lymphoma, March 2021
• Treatment-free remission and immunity in chronic myeloid leukemia
  Ureshino H. Int J Hematol, March 2021 (epub ahead of print)
• New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism
  Naka K. Int J Hematol, March 2021 (epub ahead of print)
• Efficiency of nilotinib to target chronic-phase chronic myeloid leukaemia primary mature CD34- and immature CD34+ cells
  Berger MG et al. Sci Rep, March 2021 – open access publication

Pediatric papers

• Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia
  Suttorp M et al. Cancers(Basel), February 2021 – open access publication
  
• Paediatric chronic myeloid leukemia presenting in de novo or secondary blast phase – a comparison of clinical and genetic characteristics
  Sembill S et al. Br J Haematol, March 2021 (epub ahead of print) – open access publication
  

ERSAP papers

• Analysis of the gap in PCR monitoring availability for patients with chronic myeloid leukemia in 60 low- and middle-income countries
  Rowley S et al. Cost Eff Resour Allo, March 2021 – open access publication
• Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania
  Nasser A et al. Blood Adv, March 2021 – open access publication

COVID-19 and CML/Cancer

• COVID-19 in patients with haematological malignancies: Considering the role of tyrosine kinase inhibitors
  Morale-Ortega A et al. Cancer, March 2021 (epub ahead of print) – open access publication
  
• Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review
  Prasad Meena J et al. Pediatr Blood Cancer, March 2021 (epub ahead of print) – open access publication
• Challenges and opportunities for COVID-19 vaccines in patients with cancer
  Kuderer NM et al. Cancer Invest, March 2021